Serum Institute applies to conduct local trial for Novavax vaccine: CEO

The Serum Institute of India (SII), the world's biggest vaccine maker, has applied to local authorities to conduct a small domestic trial of Novavax Inc's COVID-19 vaccine, which was found to be 89.3% effective in a UK trial. ​​​Serum expected a decision on an Indian trial of Novavax's vaccine soon, Chief Executive Adar Poonawalla told Reuters on Friday, hours after the US company reported the efficacy data.